IL132325A - Activated protein c formulations - Google Patents

Activated protein c formulations

Info

Publication number
IL132325A
IL132325A IL13232598A IL13232598A IL132325A IL 132325 A IL132325 A IL 132325A IL 13232598 A IL13232598 A IL 13232598A IL 13232598 A IL13232598 A IL 13232598A IL 132325 A IL132325 A IL 132325A
Authority
IL
Israel
Prior art keywords
formulations
activated protein
protein
activated
Prior art date
Application number
IL13232598A
Other languages
English (en)
Other versions
IL132325A0 (en
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL132325A0 publication Critical patent/IL132325A0/xx
Publication of IL132325A publication Critical patent/IL132325A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL13232598A 1997-04-28 1998-04-24 Activated protein c formulations IL132325A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4525597P 1997-04-28 1997-04-28
PCT/US1998/008386 WO1998048818A1 (en) 1997-04-28 1998-04-24 Activated protein c formulations

Publications (2)

Publication Number Publication Date
IL132325A0 IL132325A0 (en) 2001-03-19
IL132325A true IL132325A (en) 2005-07-25

Family

ID=21936854

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13232598A IL132325A (en) 1997-04-28 1998-04-24 Activated protein c formulations
IL13250298A IL132502A0 (en) 1997-04-28 1998-04-24 Improved methods for processing activated protein c

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL13250298A IL132502A0 (en) 1997-04-28 1998-04-24 Improved methods for processing activated protein c

Country Status (35)

Country Link
US (4) US6162629A (es)
EP (2) EP0875252B1 (es)
JP (2) JP4383546B2 (es)
KR (2) KR100564189B1 (es)
CN (2) CN1235638C (es)
AR (2) AR015598A1 (es)
AT (1) ATE285788T1 (es)
AU (2) AU740753C (es)
BR (2) BR9809304B1 (es)
CA (2) CA2288143C (es)
CO (2) CO4950523A1 (es)
CZ (1) CZ298429B6 (es)
DE (1) DE69828330T2 (es)
DK (1) DK0875252T3 (es)
EA (2) EA002149B1 (es)
EG (1) EG23685A (es)
ES (1) ES2234072T3 (es)
HK (1) HK1016472A1 (es)
HU (2) HU224826B1 (es)
ID (2) ID23172A (es)
IL (2) IL132325A (es)
IN (2) IN187157B (es)
MY (2) MY120984A (es)
NO (2) NO995134L (es)
NZ (2) NZ337828A (es)
PE (2) PE84799A1 (es)
PL (2) PL195642B1 (es)
PT (1) PT875252E (es)
SI (1) SI0875252T1 (es)
SV (2) SV1998000050A (es)
TR (2) TR199902631T2 (es)
TW (2) TWI242443B (es)
UA (2) UA55448C2 (es)
WO (2) WO1998048818A1 (es)
ZA (2) ZA983497B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
EA002149B1 (ru) 1997-04-28 2001-12-24 Эли Лилли Энд Компани Улучшенные способы приготовления активированного белка с
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
JP2002529515A (ja) * 1998-11-13 2002-09-10 イーライ・リリー・アンド・カンパニー ヘパリンにより誘発される血小板減少症の処置法
EP1131091B1 (en) * 1998-11-20 2003-04-02 Eli Lilly And Company Treatment of viral hemorrhagic fever with protein c
DK1133314T3 (da) * 1998-11-23 2003-04-14 Lilly Co Eli Protein C til behandling af seglcellesygdom og thalassæmi
ATE264113T1 (de) * 1998-12-10 2004-04-15 Lilly Co Eli Verwendung von protein c zur behandlung von thrombozytopenischer purpura und hämolytisches urämisches syndrom
US6758938B1 (en) * 1999-08-31 2004-07-06 Micron Technology, Inc. Delivery of dissolved ozone
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
EP1289543A2 (en) * 2000-05-24 2003-03-12 Eli Lilly And Company Formulations and methods for treating hypercoagulable states
WO2002069232A2 (en) 2001-02-19 2002-09-06 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
US7101982B2 (en) * 2001-03-30 2006-09-05 Immunex Corporation Control of ph transitions during chromatography
WO2003007686A2 (en) * 2001-07-19 2003-01-30 Dmi Biosciences, Inc. Use of copper chelators to inhibit the inactivation of protein c
EP1453529A4 (en) 2001-09-19 2007-09-26 Oklahoma Med Res Found TREATMENT OF SEPSIS WITH TAFI
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
AU2002365131B2 (en) 2001-10-15 2007-03-01 Novartis Vaccines And Diagnostics, Inc. Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (TFPI)
IL162239A0 (en) 2001-12-21 2005-11-20 Novo Nordisk Healthcare Ag Liquid composition of factor vii polypeptides
US20050143283A1 (en) * 2002-03-08 2005-06-30 Eli Lilly And Company Activated protein c formulations
EP2283856B1 (en) 2002-06-21 2017-09-20 Novo Nordisk Health Care AG Stabilised solid compositions of factor VIIa polypeptides
KR20050083841A (ko) * 2002-10-29 2005-08-26 알자 코포레이션 안정화된 고체상태 폴리펩타이드 입자
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
ATE547114T1 (de) * 2003-06-25 2012-03-15 Novo Nordisk Healthcare Ag Flüssige zusammensetzungen von factor vii polypeptiden
CN101426520A (zh) * 2004-03-17 2009-05-06 诺华疫苗和诊断公司 通过给予组织因子途径抑制剂（tfpi）治疗社区获得性重症肺炎
US20080305100A1 (en) * 2004-07-23 2008-12-11 Zlokovic Berislav V Activated Protein C Inhibits Undesirable Effects of Plasminogen Activator in the Brain
AU2006261555A1 (en) * 2005-06-23 2006-12-28 The University Of British Columbia Coagulation factor lll polymorphisms associated with prediction of subject outcome and response to therapy
ES2386972T3 (es) * 2006-05-31 2012-09-10 Genzyme Corporation Uso de polisacáridos para la estimulación de la actividad enzimática
US20100041600A1 (en) * 2006-06-09 2010-02-18 Russel James A Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
JP5179521B2 (ja) * 2007-03-05 2013-04-10 カディラ・ヘルスケア・リミテッド ペグ‐インターフェロンアルファ接合体および凍結保護剤としてラフィノースを含む組成物
KR20100014674A (ko) * 2007-03-29 2010-02-10 아보트 러보러터리즈 결정성 항-사람 ｉｌ-12 항체
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CN101969971A (zh) * 2007-11-30 2011-02-09 雅培制药有限公司 蛋白制剂及其制备方法
US20110171200A1 (en) * 2008-01-15 2011-07-14 Walley Keith R Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
BRPI0921320A2 (pt) * 2008-11-28 2018-05-22 Abbott Laboratories composições de anticorpo estáveis e métodos para estabilizar os mesmos
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP2834635A4 (en) 2012-04-03 2015-09-02 Smiths Medical Asd Inc COMPOSITIONS WITH A HEPARINE ACCUMULATIVE AND METHOD THEREFOR
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
JP6273272B2 (ja) 2012-07-04 2018-01-31 ジージー バイオテック エルエルシー 炎症性皮膚障害の治療
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
BR112015004467A2 (pt) 2012-09-02 2017-03-21 Abbvie Inc método para controlar a heterogeneidade de proteínas
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015157791A1 (en) 2014-04-16 2015-10-22 The University Of Sydney Treatment of abnormal cutaneous scarring
US11058750B2 (en) 2015-12-03 2021-07-13 Mor Research Applications Ltd. Compositions and methods for treatment of ocular diseases
HUE057856T2 (hu) * 2016-06-01 2022-06-28 Servier Ip Uk Ltd Polialkilén-oxid-aszparagináz készítményei és eljárás ezek elõállítására és alkalmazására
CN108159399B (zh) * 2017-12-29 2020-07-24 华中科技大学同济医学院附属同济医院 一种凝血蛋白酶aPC在防治糖尿病心肌病药物中的应用
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4849403A (en) * 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
AT399095B (de) * 1986-03-27 1995-03-27 Vukovich Thomas Dr Verfahren zur auftrennung von proteinen mittels gradientenelution und vorrichtung zur durchführung des verfahrens
US5175087A (en) * 1987-07-06 1992-12-29 Biopool International, Inc. Method of performing tissue plasminogen activator assay
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
JPH01226900A (ja) * 1988-03-08 1989-09-11 Green Cross Corp:The プロテインｃの精製方法
DE3823519A1 (de) * 1988-07-12 1990-01-18 Basf Ag Verfahren zur reinigung von aktiviertem protein c
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
JPH05506354A (ja) * 1990-02-09 1993-09-22 ザイモジェネティクス，インコーポレイティド 端が切り取られた軽鎖を有する活性プロテインｃ
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5040862A (en) 1990-05-07 1991-08-20 Corning Incorporated Method of trimming optical power
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
US5413732A (en) * 1991-08-19 1995-05-09 Abaxis, Inc. Reagent compositions for analytical testing
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5395923A (en) * 1993-02-23 1995-03-07 Haemacure-Biotech, Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out"
JP3043558B2 (ja) * 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
JP2886061B2 (ja) * 1993-10-29 1999-04-26 財団法人化学及血清療法研究所 プロテインｃもしくは活性化プロテインｃの安定化方法及び安定化組成物
JPH07165605A (ja) * 1993-12-16 1995-06-27 Teijin Ltd 活性化プロテインｃバイアル
NZ270271A (en) * 1994-01-05 1996-07-26 Lilly Co Eli Minimizing protein c degradation
JPH08301786A (ja) * 1995-05-11 1996-11-19 Mochida Pharmaceut Co Ltd 吸収性骨疾患予防・治療剤
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
EA002149B1 (ru) * 1997-04-28 2001-12-24 Эли Лилли Энд Компани Улучшенные способы приготовления активированного белка с
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
IL132502A0 (en) 2001-03-19
KR20010020242A (ko) 2001-03-15
KR100564189B1 (ko) 2006-03-27
SV1998000050A (es) 1999-01-13
AU740753B2 (en) 2001-11-15
HUP0003401A2 (hu) 2001-02-28
IN187157B (es) 2002-02-16
JP4383546B2 (ja) 2009-12-16
TR199902529T2 (xx) 2000-02-21
PL336889A1 (en) 2000-07-17
HU224826B1 (en) 2006-02-28
CA2288143A1 (en) 1998-11-05
MY120984A (en) 2005-12-30
HK1016472A1 (en) 1999-11-05
HUP0100284A3 (en) 2003-08-28
NO995134L (no) 1999-12-21
PE86299A1 (es) 1999-09-17
CA2287267A1 (en) 1998-11-05
CZ298429B6 (cs) 2007-10-03
KR20010020325A (ko) 2001-03-15
HUP0100284A2 (hu) 2001-06-28
NO995198L (no) 1999-10-25
MY118591A (en) 2004-12-31
TR199902631T2 (xx) 2000-01-21
CA2288143C (en) 2012-08-21
KR100450856B1 (ko) 2004-10-02
TW585871B (en) 2004-05-01
ES2234072T3 (es) 2005-06-16
CO4940438A1 (es) 2000-07-24
EP0875252B1 (en) 2004-12-29
ATE285788T1 (de) 2005-01-15
EP0875252A3 (en) 2000-07-26
NZ337828A (en) 2001-06-29
CN1261280A (zh) 2000-07-26
JP4383547B2 (ja) 2009-12-16
UA55448C2 (uk) 2003-04-15
PL195642B1 (pl) 2007-10-31
NZ500346A (en) 2001-08-31
PT875252E (pt) 2005-03-31
CA2287267C (en) 2006-08-15
BR9809304A (pt) 2000-10-17
AR015598A1 (es) 2001-05-16
US6436397B1 (en) 2002-08-20
US6395270B1 (en) 2002-05-28
IL132325A0 (en) 2001-03-19
EA199900980A1 (ru) 2000-04-24
HUP0003401A3 (en) 2003-01-28
CZ381099A3 (cs) 2000-03-15
CN1254284A (zh) 2000-05-24
AU743531B2 (en) 2002-01-31
DE69828330T2 (de) 2005-10-13
US6159468A (en) 2000-12-12
AU7258998A (en) 1998-11-24
PE84799A1 (es) 1999-09-16
EG23685A (en) 2007-05-09
AU740753C (en) 2002-10-10
PL195090B1 (pl) 2007-08-31
WO1998048822A1 (en) 1998-11-05
ZA983496B (en) 1999-10-25
CN1235638C (zh) 2006-01-11
DE69828330D1 (de) 2005-02-03
IN183798B (es) 2000-04-15
EP0875563A3 (en) 2000-08-02
ID22933A (id) 1999-12-16
DK0875252T3 (da) 2005-04-25
EP0875563A2 (en) 1998-11-04
JP2001527543A (ja) 2001-12-25
EA004881B1 (ru) 2004-08-26
PL336420A1 (en) 2000-06-19
WO1998048818A1 (en) 1998-11-05
NO995134D0 (no) 1999-10-21
CO4950523A1 (es) 2000-09-01
EP0875252A2 (en) 1998-11-04
AU7161898A (en) 1998-11-24
US6162629A (en) 2000-12-19
AR012010A1 (es) 2000-09-13
JP2001524111A (ja) 2001-11-27
NO995198D0 (no) 1999-10-25
SI0875252T1 (en) 2005-06-30
BR9809304B1 (pt) 2011-02-08
ID23172A (id) 2000-03-23
EA199900979A1 (ru) 2000-06-26
SV1998000051A (es) 1998-12-11
UA73071C2 (en) 2005-06-15
BR9809292A (pt) 2000-07-04
ZA983497B (en) 1999-10-25
TWI242443B (en) 2005-11-01
CN1227025C (zh) 2005-11-16
EA002149B1 (ru) 2001-12-24

Similar Documents

Publication Publication Date Title
EG23685A (en) Activated protein c formulations
EP1113799A4 (en) PROTEIN-BASED PREPARATION
GB9715751D0 (en) Formulations
GB9703681D0 (en) Protein complemention
GB9719879D0 (en) Protein
EP1018551A4 (en) MEGSINE PROTEIN
EP1012262A4 (en) HFLP PROTEIN HFLP
EP1038958A4 (en) HUMAN NAP1 PROTEIN
GB9715064D0 (en) Protein expression
ZA984322B (en) Sucrose-binding proteins
GB9720784D0 (en) Protein
AU7259898A (en) Human smt-3 like protein
AU7285298A (en) Human tsc-22-like protein
GB9720785D0 (en) Protein
GB9703103D0 (en) Protein
GB9719670D0 (en) Protein
EP0983091A4 (en) OBESITY PROTEIN COMPOSITION
EP0971742A4 (en) Obesity protein formulations
GB9706119D0 (en) Novel protein
GB9704252D0 (en) Novel protein
GB9714075D0 (en) Novel protein
GB9703850D0 (en) Novel protein
GB9703827D0 (en) Novel protein
GB9703100D0 (en) Formulations
GB9703099D0 (en) Formulations

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees